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T he discovery of superantigens and their biologic ef-fects has elicited much excitement in the scientific and medical communities. Because superantigens have the potential to interfere with recognition and elimination of conventional antigens and thus normal 
host defense or self-tolerance, intensive investigations on their 
physical properties and biologic effects have been undertaken and 
are currently being performed in many areas of fundamental and 
applied research including investigative dermatology. Here, we 
have therefore attempted to outline some basic properties of super-
antigens to see how the relationship between immune-mediated 
disease and superantigens could be investigated. It is not within the 
scope of this editorial/comment to review superantigens. The in-
terested reader is referred to a recent series of excellent reviews [1]. 
Superantigens are ge~e produ~ts that are recognized by a large 
fraction of T cells. ThiS recognltlon IS mediated by the clonally 
distributed receptor for antigen, i.e., the T-cell receptor (TCR). 
The TCR of most T cells is composed of a heterodimeric o:p TCR 
that contains, in analogy to immunoglobulins, constant regions 
junctional, N-regions, and variable (V) regions. This allows the 
immune system to generate on the order of 10 12 different clonally 
distributed TCR. Whereas the interaction of conventional antigens 
with the TCR requires multiple elements of both the 0: and p chains 
of the TCR, superantigens interact with a restricted set of T~R 
with distinct V p elements. This results in superantigens reacting 
with a large fraction ofT cells, in some cases up to 20% ofT cells. 
Some of these Vp elements can be detected by monoclonal antibod-
ies, whereas others must be identified by DNA sequence analysis. 
The genes for the TCR Vp elements are located close together on 
the DNA and all share a significant sequence homology. Some of 
the identified superantigens have been determined to be microbial 
gene products. One class interacts with bacteria and has previously 
been characterized as toxins. For example, staphylococcal entero-
tOxin B (SEB) was identified in StaphylocoCClls allrellS isolates asso-
ciated with acute gastro-enteritis. The activity responsible for the 
gastro- intestinal sympt?ms and the activity on T ~ells ~re not lo-
cated on the same protem site because chemical modification ofSEB 
can destroy its ability to cause gastrointestinal symptoms without 
affecting the T-cell stimulatory activity. Recombinant SEB reacts 
selectively with the murine TCR Vp 7 and 8.1-8.3 elements and 
human TCR Vp 3, 12, 14, 15, 17, and 20 elements. Other S. 
aureus-derived toxins well known to dermatologists are the toxic 
shock syndrome toxin-1 and the exfoliative toxin associated with 
the staphylococcal scalded skin syndrome. These toxins also possess 
superantigenic properties. Ba~terial superantigens do not require 
processing by antlgen-presentmg cells to exert effects on T cells as 
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do conventional antigens. They can directly bind to major histo-
compatibility complex (MHC) class II molecules on one hand and 
to the relevant Vp chains on the other. This multimolecular inter-
action results in T-cell response. Experiments with mutated MHC 
class II molecules gave evidence that bacterial superantigens bind to 
t~le outer side of the pocket formed by the MHC class II polypep-
tides. ConventIOnal antigen is bound within the MHC pocket once 
It ha~ been processed within the cell. Thus superantigens appear to 
reqUIre mteractlOn with both MHC class II molecules and TCR Vp 
elements, but do not display the typical MHC class II restriction 
seen with conventional antigens. 
The investigation of another class of superantigens has recently 
re.sulted in a series of important findings. The minor lymphocyte 
stlmul:tlllg (MIs) determinants of the mouse have puzzled immu-
nologists for years. These determinants were discovered in the 
1970s by the mixed lymphocyte reaction because the frequency of 
respondmg T cells in a non-immunized population was on the order 
of 1 :10 to 1 : 30. This was higher than the frequency of allo-MHC 
react~ve T cells that were also investigated by the mixed lymphocyte 
reaction. The frequency of T cells for conventional antigens is on 
the order of 1 : 105 and thus can not be detected in a primary lym-
phocyte culture. 
Although Mis reactivity required the presence of MHC class II+ 
cells, MIs determinants mapped outside the MHC. When it was 
discovered that Mis determinants mapped to the integration sites of 
the mammary tumor viruses (MTV), some light began to be shed 011 
the M is system. MTV are endogenous or exogenous retroviruses 
that integrate into the mouse genome and can cause manunary 
tumors. Tod~y, there is good evidence that MTV are responsible for 
the superantlgeJ11c effects of all the known Mis determinants. Su-
perantigenic effects could be induced in MTV- sucklings fed with 
milk from m~thers harboring a distinct MTV type. In addition, 
lruce transge111c for MTV showed the relevant superantigenic ef-
fects. Recently, the ORF gene of MTV was transfected into B-cell 
lines and introduced into the germline to produce transgenic mice. 
The transfectants as well as the transgenic animals exhibited the 
expected superantigenic effects thus identifying the responsible 
MTV gene. MTV-dependent superantigenic activity was high in 
normal B cells but low or nondetectable in dendritic cells and mac-
ro~hage.s. Only minute quantities of the ORF gene product could 
be IdentIfied at the surface ofB cells. Comparing the sequence of the 
ORF gene of different MTV strains it has become clear that the 
extracellular carboxy terminal is polymorphic and correlates with 
Vp selection. Theyrecise molecular mechanisms of MTV-depen-
dent superantlgel1lc effects, mcluding the requirement for process-
ing of the ORF protein, remain to be elucidated. Cell-transfer ex-
periments revealed that B cells as well as CD8+ T cells can induce 
superantigen effects in superantigen-ncgative recipients. The 
mechanism of the superantigen effect transferred by CD8+ T cells is 
for the moment not clear because these cells cannot directly stimu-
late T cells due to the lack MHC class II expression. 
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As T cells can recognize antigen only in physical association with 
major histocompatibiliry (MHC) gene products, investigators de-
termined the MHC requirement for superantigen recognition. In 
general, it was found that MHC class II gene products were required 
for superantigen recognition, although recently activation ofT cell s 
in the presence of MHC class n- cell lines has been observed. In 
sharp contrast to the recognition of conventional antigen, no re-
striction to self-MHC was found even though preference for certain 
MHC class II isorypes and haplorypes was noted. 
What are the effects of superantigen activation ofT cells? In vivo 
experiments have shown that administration of superantigen or 
cells containing superantigens can have three principal effects that 
are selective for T cells with the relevant V p elements: 1) T cells can 
be deleted intrathymically or extrathymically; 2) T cells may ex-
pand in relative and absolute numbers; or 3) T cells may show 
altered responsiveness such as unresponsiveness to stimulation with 
conventional antigen also referred to as "energy." The complexiry 
of superantigen biology was further demonstrated when opposing 
effects on the relevant V P bearing T cells were observed depending 
on length of time since administration of superantigen. For exam-
ple, the injection ofSEB first leads to an expansion, subsequently to 
anergy, and finally to disappearance (deletion) of the relevant 
postthymic T cell s. Irl vitro assays have been very extensively em-
ployed for the study of superantigenic effects. Depending on the 
conditions, activation and expansion, but also induction, of anergy 
have been observed in T cells. The response ofT cells depends not 
only on their developmental and activational state but also on the 
accessory signals provided by the superantigen presenting cell , 
which may explain in part the variable responses ofT cells to super-
antigens. 
HOW CAN WE STUDY THE ROLE OF 
SUPERANTIGENS IN IMMUNE-MEDIATED DISEASE? 
From the study of the biology of superantigens, a seductive hypoth-
esis has emerged that superantigens originating from microorga-
nisms may induce or contribute to T cell- mediated disease. One 
can imagine various ways in which superantigens may induce 
T-cell - dependent disease. Superantigens may lead to deletion or 
unresponsiveness ofT cells that are crucial for host defense or toler-
ance. It is questionable whether such a mechanism exists because 
inbred mice carry multiple MTV with deletion of the relevant Vp 
bearing T cells but do not develop undue susceptibili ry to infection 
or autoimmunity. It is also possible that anergic but potentially 
self-reactive T cells are activated by superantigens and thus induce 
or contribute to disease. Finally, it can also be hypothesized that 
normal T cells become functionally altered. Such altered T cells 
may not be capable of fu lfilling their normal function in host de-
fense or self-tolerance, thus causing disease. 
Although there is no fully convincing report that animals ex-
posed to superantigen develop T -cell- mediated disease, this should 
nevertheless be further tested. Today, it is not clear whether a su-
perantigen encounter results in unresponsiveness or whether the 
function of superantigen-activated T cells can be rescued by presen-
tation of conventional antigen thus resulting in disease such as au-
toimmuniry. To address the potential roles of superantigen in au-
toimmune diseases, one should take advantage of the simple 
experimental models of autoimmune and the excellent transgenic 
mouse models avai lable. Conditions with high susc::eptibi liry to au-
toimmune disease may be required for such experiments because 
administration of superantigen may only induce disease in animals 
with other factors or genes that favor the development of autoim-
munity. For example, in chronic relapsing experimental allergic 
encephalomyelitis (EAE) , a varying percentage of mice injected 
with the autoantigen myelin basic protein develop disease. Because 
the disease-causing T cel ls express V pS .2, SEB can be used to address 
the question of whether a superantigen can trigger autoimmuniry in 
mice that are prone to autoimmune disease. In addition, in these 
mice, the question can be asked whether anima ls that have recov-
ered from the first attack of EAE can be forced into relapse with 
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superantigen. To cite one example of transgenic mice useful for 
such an analysis, the effect of superantigens can be tested on animals 
that are transgenic for a TCR that recognizes an autoantigen on the 
P cells of the pancreas and cross reacts with SEB [2] . Ifin such models 
the autoimmune disease is dependent on the relevant T cells, further 
evidence for a role of superantigens in autoimmuniry could be col-
lected. 
To date, however, there is only limited evidence that T cells 
activated by superantigen have the potential to mediate disease. 
T cell s expanded in vitro with superantigens induce inflammation 
when injected into naive animals [3]. The possibiliry that T cells 
activated in vivo by superantigen may not have the same properties as 
T cells activated in vitro limits the value of this finding. 
In clinical settings, cause-effect relations can often not be tested 
directly. Therefore, the question arises of what criteria should be 
fulfilled to postulate a cause-effect relation between superantigen 
derived from microorganisms and immune-mediated disease. W e 
propose that the following correlations should be analyzed when a 
cause-effect relationship is postulated for superantigens and human 
disease. 1) A good correlation between the induction or exacerba-
tion of a T -cel l- mediated pathology and the identification of a 
superantigen-producing microorganism(s) has to be documented. 
2) The suspected microorganism(s) shou ld be isolated and the VP-
selective effect of its (their) superantigen(s) determined. 3) The 
T-cell effects induced by the superantigen(s) from this (these) uu-
croorganism(s) have to be correlated with the disease-associated 
T-cell abnormalities. In the case of deletion or expansion ofT cells 
with distinct Vp subsets, this may be possible by determining the 
relative number ofT cells carrying defined Vp determinants using a 
panel of appropriate monoclonal antibodies and comparing them 
with expected numbers. In the case of nonresponsiveness ofT cells, 
reduction of interleukin-2 secretion after monoclonal antibody 
crosslinking of the TCR could be measured. Determination of dis-
ease-associated T-cell numbers may not yield clear-cut results when 
multiple superantigens and multiple Vp families are involved. In 
addition, simple determination of relative cel l numbers does not 
detect superanti gen-induced functional alterations within a distinct 
Vp subset causing disease. Moreover, if the Vp-selective effect is 
anatomically compartmentalized it may not be detected easily. 4) 
Exposure to superantigen derived from the suspected infectious 
agent should correlate with flare or induction of disease as well as 
with the expected alteration in T cells. Clearly, the difficulry lies in 
the establishment of the entire network of correlations. One has to 
bear in mind that a lack of correlation may not disprove the role of 
superantigen in T -cell - mediated disease. The crucial step that i 
waiting to be taken is the demonstration that superantigen-induced 
quantitative and/or qualitative alterations of T cells may induce or 
exacerbate disease. 
Examples of diseases in which superantigenic effects have been 
suspected to be operative are rheumatoid arthritis [4,5]' human 
immunodeficiency virus infection [6], and Kawasaki's disease [7]. 
Furthermore, administration of superantigen has been observed 
to induce arthritis flare in a model of streptococcal cell wall-
induced arthritis [8]. Acute guttate psoriasis may be preceded by a 
streptococcal infection and the skin of patients with atopic der-
matitis is heavily colonized by S. at"eus. Because T cells are sus-
pected of playing a crucial role in both disorders, superantigens 
may playa precipitating or aggravating role. However, evidence 
published to date for streptococcal or staphylococcal superantigenic 
effects in these disorders is scant [9 -11]. As more monoclonal anti-
bodies to various human Vp families of the TCR are becoming 
available further studies on this topic are expected in the near 
future . 
It is possible that the symbiosis of superantigen-producing micro-
organism and host may not result in immediate and overt disease. 
Because this interaction has survived evolution, it may provide all 
advantage for selection. It will be the task of future investigations 
undertaken by basic and clinical scientists to further elucidate the 
relationship between superantigen and T -cell- mediated immuno-
pathology. 
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